



ISPOR Russia St. Petersburg Chapter

Annual Report 2017

To:

Board of Directors

International Society for Pharmacoeconomics and

Outcomes Research

505 Lawrence Square Boulevard South

Lawrenceville, TO 08648 USA

PREPARED BY

Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; alex.kolbin@mai.ru

Yulia E. Balykina, PhD, St Petersburg State University, faculty of Applied Mathematics and Control Processes, associate professor, julia.balykina@gmail.com

President of ISPOR Russia St. Petersburg Chapter

Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia

President-Elect

Sergey Zyryanov, MD, PhD, Doctor of Medical Sciences, professor, Head of the Department of Pharmacology of RUDN University, sergey.k.zyryanov@gmail.com

Director

Dmitry Belousov, MD, Journal “Good clinical practice” (chief editor), clinvest@mail.ru

Secretary

Alexey A. Kurylev, MD, Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.

For more information on Chapter, please visit at http://www.ispor.org/regional_chapters/Russia-StPetersburg/index.asp and <http://www.labclinpharm.ru>.

Activities of the Chapter in 2017:

I. Publications in the field of pharmacoeconomics and health technology assessment:

№	Title	Journal	Authors
1	Pharmacoeconomic analysis of the use of parnaparin (Fluxum®) for the prevention of venous thromboembolic complications in surgical interventions and for the treatment of superficial thrombophlebitis	Clinical pharmacology and therapy. 2017; 26(1):66-71.	Kolbin A.S., Galankin T.L.
2	Comparative pharmacoeconomic assessment of the type 2 diabetes treatment with insulin degludec and insulin glargine in basal-bolus insulin therapy	Diabetes Technology & Therapeutics. 2017; 19(S1):A132. Downloaded from online.liebertpub.com by 66.102.9.148 on 02/22/17.	M. Shestakova, A. Kolbin, G. Galstyan, A. Kurilev, Z. Wenlong, J. Balykina, M. Proskurin, Y. Alekseeva, E. Startseva
3	Complex clinical and economic assessment of omalizumab in severe uncontrolled bronchial asthma in Russia	Clinical pharmacology and therapy. 2016; 25(5):80-85.	A.S. Kolbin, L.S. Namazova- Baranova, E.A. Vishneva, M.Yu. Frolov, T.L. Galankin, A.A. Alekseeva, E.A. Dobrynina

4	Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabine	Modern oncology. 2017; 19 (1):48–53.	Kolbin A.S., Mosikyan A.A., Kurilev A.A., Balykina Yu.E., Proskurin M.A.
5	Comparative pharmacoeconomic evaluation of basal-bolus insulin therapy with insulin degludec and insulin glargine in diabetes 2 type treatment	Proceedings of the III All-Russian endocrinological congress with international participation "Innovative technologies in endocrinology" (March 1-4, 2017, Moscow)	Kolbin A.S., Shestakova M.V., Galstyan G.R., Wenlong, J., Mosikyan A.A., Kurilev A.A., Balykina Yu.E., Proskurin M.A., Alekseeva Y.G., Startseva E.Yu.
6	Evaluation of final and surrogate endpoints of drugs included in reimbursement lists in 2016	Remedium, 2017. Vol. 4, pp.42-46.	Kolbin A.S., Omelyanovskiy V.V., Kurylev A.A.
7	Pharmacoeconomic analysis of Flemoclav Solutab® use in adult patients with acute sinusitis in routine outpatient clinical practice in Russia	Good clinical practice. 2017, Vol. 1, pp.4-11.	Kolbin A.S., Vilum I.A., Poskurin M.A., Balykina Y.E.
8	Pharmacoeconomic analysis of brentuximab vedotin therapy in relapsed or refractory CD30+ systemic anaplastic large cell lymphoma in patients over 18 years of age: health budget impact analysis	PHARMACOECONOMIC S. Modern pharmacoeconomics and pharmacoepidemiology. 2017; 10(1):39-45. DOI: 10.17749/2070-4909.2017.10.1.039-045	Kolbin A.S., Vilum I.A., Balykina Yu.E., Proskurin M.A.

9	Pharmacoepidemiology of antimicrobial agents in pregnant women: a non-interventional retrospective study	Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1):67-72.	Kolbin A.S., Sidorenko S.V., Zagorodnikova K.A., Lobzin Yu.V., Ivanov D.O., Shabalov N.P., Mikhailov A.V., Klimko N.N., Dolgov G.V., Shmidt A.A., Galankin T.L., Kurylev A.A., Malikova E.A.
10	Pharmacoeconomic analysis of dexamethasone intravitreal implant for the treatment of diabetic macular edema in Russia	ISPOR 22nd Annual International meeting Research Abstracts, May 20-24, 2017, Boston, MA, USA. Value in Health. 2017; 20(5):A1-A383. PSS16.	Kolbin A., Galankin T., Kaleev A.
11	Pharmacoepidemiology of Antimicrobials in Neonatology in Russia, Retrospective Analysis of Medical Records	Clinical Therapeutics. 2017; 39(8):e1-e2. DOI: https://doi.org/10.1016/j.clinthera.2017.07.019	T. Galankin, A. Kolbin, S. Sidorenko, Y. Lobzin, D. Ivanov, N. Shabalov, A. Mikhailov, N. Klimko, G. Dolgov, A. Shmidt, A. Kurylev, E. Malikova
12	Pharmacoepidemiology of Antimicrobials in Pregnant Women And Women After Childbirth In Russia,	Clinical Therapeutics, 2017; 39(8):e2. DOI: http://dx.doi.org/10.1016/j.clinthera.2017.07.020	T. Galankin, A. Kolbin, S. Sidorenko, K. Zagorodnikova, Y.

	Retrospective Analysis of Medical Records.		Lobzin, D. Ivanov, N. Shabalov, A. Mikhailov, N. Klimko, G. Dolgov, A. Shmidt, A. Kurylev, E. Malikova.
13	Health economic analysis of vemurafenib and dabrafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation	Good clinical practice. 2017, Vol. 1, pp. 11-19.	Kolbin A.S., Kurylev A.A., Balykina Y.E., Poskurin M.A.
14	Economic assessment of the effectiveness and safety of the commonly practiced perioperative antibiotic prophylaxis (based on an earlier epidemiological survey of multidisciplinary hospitals)	PHARMACOECONOMIC S. Modern pharmacoeconomics and pharmacoepidemiology. 2017; 10(2):3-11. DOI:10.17749/2070-4909.2017.10.2.003-011	Gomon Y.M., Kolbin A.S., Sidorenko S.V., Kuzhel' A.M., Repina A.V., Lobzin Y.V., Balykina Y.E.
15	Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib+capecitabine in patients with HER2+ breast cancer and central nervous system metastases	Good Clinical Practice. 2017, Vol. 2, pp. 4-11.	Kolbin A.S., Kurylev A.A., Balykina Y.E., Poskurin M.A., Naskhletashvili D.R.
16	Economic Consequences of Common Practice Community Acquired Pneumonia Treatment Based on Epidemiological Study at Multidisciplinary Hospitals	Medical Technologies. Assessment and Choice. 2017; 3(29):65-75.	Gomon Y.M., Kolbin A.S., Balykina Yu.E., Sidorenko S.V., Ivanov I.G., Lobzin Yu.V.

17	Cost-effectiveness analysis of the current practice of antibiotic therapy of community-acquired pneumonia in multidisciplinary hospitals	Clinical Pharmacology and Therapy. 2017; 26(4):92-96.	Gomon Y.M., Kolbin A.S., Balykina Yu.E., Sidorenko S.V., Ivanov I.G., Kuzhel A.M., Repina A.V., Lobzin Yu.V.
18	Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy	Problems of endocrinology. 2017; 63(5): 307-319. DOI: http://dx.doi.org/10.14341/probl2017635307-319	Kolbin A.S., Shestakova M.V., Galstyan G.R., Zhao W., Mosikyan A.A., Kurylev A.A., Balykina Y.E., Proskurin M.A., Alekseeva Y.G., Startseva E.Y.
19	Ranking Algorithm for Medical Research Results Based on the Levels of Evidence at the Stage of Getting Answers to Search Queries	Medical Technologies. Assessment and Choice. 2017; 3(29):11–21.	M.V. Kamalov, V.Yu. Dobrynin, Yu.E. Balykina, A.S. Kolbin, E.V. Verbitskaya
20	Pharmacoeconomic Analysis of Trastuzumab Emtanzine in Patients with Metastatic Breast Cancer and Central Nervous System Metastases	Value in Health. 2017; 20(9):A438. DOI: http://dx.doi.org/10.1016/j.jval.2017.08.228	Kolbin A., Kurylev A., Balykina Y., Proskurin M.
21	Pharmacoeconomic Analysis of Obinutuzumab Plus Chlorambucil in Patients with Previously Untreated Chronic Lymphocytic Leukemia and Coexisting Conditions	Value in Health. 2017; 20(9):A438. DOI: http://dx.doi.org/10.1016/j.jval.2017.08.231	Kolbin A., Vilum I., Balykina Y., Proskurin M.

22	Pharmacoeconomic Analysis of Ixabepilone Monotherapy in Patients with Advanced or Metastatic Breast Cancer Resistant To Anthracyclines, Taxanes and Capecitabine	Value in Health. 2017; 20(9):A440. DOI: http://dx.doi.org/10.1016/j.jval.2017.08.241	Kolbin A., Mosikian A., Kurylev A., Balykina Y., Proskurin M.
23	The Analysis Of Final And Surrogate Effectiveness Criteria Used In Health Economic Studies Of Drugs Submitted Into The Reimbursement In Russia In 2016	Value in Health. 2017; 20(9):A678. DOI: http://dx.doi.org/10.1016/j.jval.2017.08.1683	Kolbin A., Omelianovskiy V., Kurylev A.
24	Analysis of Effectiveness Criteria In Pharmacoeconomic Studies of Antimicrobial Therapeutic Agents Proposed for Inclusion In The Essential Drug List (RUSSIA) In 2014-2016	Value in Health. 2017; 20(9):A731. DOI: http://dx.doi.org/10.1016/j.jval.2017.08.1993	Kolbin A., Gomon Y.
25	Decision modelling for the evaluation of diabetes outcomes	PHARMACOECONOMIC S. Modern pharmacoeconomics and pharmacoepidemiology. 2017; 10(3):47-58. DOI: http://dx.doi.org/10.17749/2070-4909.2017.10.3.047-058	A.A. Mosikian, W. Zhao, T.L. Galankin, A.S. Kolbin
26	Comparative pharmacoeconomic evaluation of the use of afatinib and gefitinib in therapy for lung cancer	Oncology Issues. 2017; 63(1):38-51.	Fedyaev D.V., Ignatieva V.V., Derkach E.V., Zyryanov S.K., Laktionov K.K., Semiglazova T.Yu.

27	Pharmacoeconomic study of the use of thrombopoietin receptor agonists in adult patients with chronic idiopathic thrombocytopenic purpura in the Russian Federation	Hematology and Transfusiology. 2017; 62(1):20-25. DOI: 10.18821/0234-5730-2017-62-1-20-25	Krysanov I.S., Zyryanov S.K., Krysanova V.S.
28	Comparative evaluation of clinical and economic efficiency of paliperidone in various dosage forms used in patients with schizophrenia	S.S. Korsakov Journal of Neurology and Psychiatry. 2017; 117(2):85-92.	Dyakov I.N., Zyryanov S.K.
29	Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma	Good clinical practice. 2017; 2: 12-24.	Kosolapov. E.G., Kochenkov F.S., Ziryryanov S.K., Gladkov O.A.
30	Clinical and pharmacoeconomic aspects of anti-TNF therapy change for medical reasons	Good clinical practice. 2017; 2: 35-42.	Gushchina U.S., Zyryanov S.K., Orlikhina I.A.
31	Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis	Modern Rheumatology Journal. 2017; 11(2):88-95. (In Russ.) DOI:10.14412/1996-7012-2017-2-88-95	Zyryanov S.K., Dyakov I.N., Nedogoda S.V., Frolov M.Y., Salasyuk A.S.
32	Pharmacoeconomic Effectiveness of the Inclusion of Glycopyrronium Bromide into the Program of Reimbursement of Essential Drugs for Patients with Chronic Obstructive Pulmonary Disease	Medical Technologies. Assessment and Choice. 2017; 27(1):35-45.	Dyakov I.N., Zyryanov S.K.
33	Burden of Childhood Rotavirus Disease in the Outpatient Setting of the Russian Federation	Pediatr Infect Dis J. 2017; 36(5):472-476. DOI: 10.1097/INF.0000000000001472	Lobzin Y.V., Kharit S.M., Goveia M.G., O'Brian M.A.,

			Podkolzin A.T., Blokhin B.M., Bekhtereva M.K., Rudakova A.V., Tikunov N.V.
34	The burden of rotavirus gastroenteritis, as the rationale for routine vaccination	Medical Council. 2017; 4: 73-78. DOI: http://dx.doi.org/10.21518/2079-701X-2017-4-73-78	S.M. Kharit, M.K. Bekhtereva, J.V. Lobzin, A.V. Rudakova, A.T. Podkolzin, N.V. Tikunova
35	Protease inhibitor narlaprevir in therapy of hepatitis C virus genotype 1 infection in treatment-naïve patients without cirrhosis: pharmacoeconomic evaluation	Journal Infectology. 2017; 9(1):100-103. (In Russ.) DOI:10.22625/2072-6732-2017-9-1-100-103	Rudakova A.V., Gusev D.A., Uskov A.N., Konovalova L.N., Lobzin Y.V.
36	Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)	Journal Infectology. 2017; 9(2):101-110. (In Russ.) DOI:10.22625/2072-6732-2017-9-2-101-110	Rudakova A.V., Gusev D.A., Uskov A.N., Konovalova L.N., Lobzin Y.V.
37	The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines	Journal Infectology. 2017; 9(2):17-22. (In Russ.) DOI:10.22625/2072-6732-2017-9-2-17-22	Kharit S.M., Rudakova A.M., Uskov A.N., Konovalova L.N., Lobzin Y.V.
38	Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension	Therapeutic archive. 2017; 89(3):72-77. DOI:10.17116/terarkh201789372-77	Moiseeva O.M., Rudakova A.V.
39	Comparative analysis of laparoscopic and laparotomic panhysterectomy costs in patients with early stage endometrial cancer	Tumors of female reproductive system. 2017; 13(1):49-58. DOI: 10.17650/1994-4098-2017-13-1-49-58	O.A. Smirnova, A.M. Belyaev, I.V. Berlev, A.V. Rudakova, A.P. Karitskiy

40	Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease	S.S. Korsakov Journal of Neurology and Psychiatry. 2017; 117(6-2):96-100. DOI: 10.17116/jnevro201711762 96-100	Rudakova A.V., Levin O.S.
41	Pharmacoeconomic aspects of biosimilars	Modern oncology. 2017; 19 (1):42-47.	Tryakin A.A., Rudakova A.V., Fogt S.N., Vaganov A.S., Tolkacheva D.G.
42	Pharmacoeconomic aspects of non-small cell lung cancer immunotherapy	PHARMACOECONOMIC S. Modern pharmacoeconomics and pharmacoepidemiology. 2017;10(2):62-67. DOI:10.17749/2070-4909.2017.10.2.-62-68	Rudakova A.V., Protsenko S.A., Koroleva I.A.
43	Pharmacoeconomic Aspects of Combined Treatment of Advanced Parkinson's Disease	Nervous diseases. 2017; 2: 30-34.	Rudakova A.V., Levin O.S.
44	Immunotherapy of non-small cell lung cancer: clinical and pharmacoeconomic aspects	Proceedings of the XII International Scientific Congress "Rational Pharmacotherapy", St. Petersburg, 2017; pp. 153-154.	Rudakova A.V., Protsenko S.A.
45	Clinical and economic evaluation of inhalation anesthetics	Messenger of Anesthesiology and Resuscitation. 2017; 14(5):8-19.	Belousov D.Yu., Cheberda A.E., Gubaydulin R.R.
46	Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy	Messenger of Anesthesiology and	Polushin Yu.S., Sokolov D.V.,

		Resuscitation. 2017; 14(6):6-20.	Belousov D.Yu., Cheberda A.E.
47	Comparative pharmacoeconomic analysis of anti-VEGF therapy for age-related macular degeneration	Good Clinical Practice. 2017; 4: 5-16.	Belousov D.Yu., Cheberda A.E., Shishkin M.M.
48	Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema	Good Clinical Practice. 2017; 4: 17-30.	Belousov D.Yu., Cheberda A.E., Shishkin M.M.
49	Pharmacoeconomic assessment of intermittent and continuous renal replacement therapy	Messenger of Anesthesiology and Resuscitation. 2017; 14(6):6-20.	Polushin Yu.S., Sokolov D.V., Belousov D.Yu., Cheberda A.E.
50	Clinical project management	1st ed. - M.: Buki Vedi: Publishing house OKI, 2017. - 676 p.	under Ed. of Belousov D.Yu., Zyryanov S.K., Kolbin A.S.
51	Cost of type 2 diabetes mellitus in Russian Federation: results of pharmacoepidemiological study FORSIGHT-DM2	Diabetes Mellitus. 2017; 20(6), IN PRINT	Dedov I.I., Kalashnikova M.F., Belousov D.Yu., Kolbin A.S., Rafalskiy V.V., Cheberda A.E., Kantemirova M.A., Zakiev V.D.
52	Evaluation of direct cost in case of insulin glargine-100 switching to insulin glargine-300 in diabetes mellitus in real clinical practice	Good Clinical Practice. 2017; 3: 11-22.	Belousov D.Yu. , Karpov O.I.
53	Post-authorization clinical trials	Good Clinical Practice. 2017; 1: 20-23.	Belousov D.Yu.

54	Non-interventional studies	Good Clinical Practice. 2017; 1: 24-33.	Belousov D. Yu.
55	Pharmacoepidemiological studies: methodology and regulation	Good Clinical Practice. 2017; 1: 34-41.	Belousov D. Yu., Cheberda A.E.
56	Drug utilization research	Good Clinical Practice. 2017; 1: 42-45.	Cheberda A.E.
57	Cost-effectiveness and cost-utility analysis of gene therapy drug Neovasculgen in the treatment of chronic lower limb ischemia	Medical Council. 2017; 14: 132-135. DOI: http://dx.doi.org/10.21518/2079-701X-2017-14-132-135	Plavinsky S.L., Shabalkin P. I.
58	The cost-effectiveness, cost-utility, and influence on the budget of the Russian Federation analysis of replacement of the I generation 5TH3 receptor antagonists with palonosetron for the prevention of chemotherapy-induced nausea and vomiting	Pharmateca. 2017; 17(350):50-54.	Plavinsky S.L., Shabalkin P. I.
59	Pharmacoeconomical evaluation of brivaracetam – the new drug for the adjunctive treatments in uncontrolled focal epilepsy – in Russia	Medicine. 2017; 2(18):45-54.	Plavinskiy S.L., Shabalkin P. I.
60	Use of Creon® Micro in the treatment of exocrine pancreatic insufficiency in children with cystic fibrosis. Budget impact analysis	Medicine. 2017; (2):1-13	Plavinsky S.L., Barinova A.N.
61	The economic consequences of the introduction of Creon Micro into the basic therapy of exocrine	Evidence-based gastroenterology. 2017; (2): 46-53.	Plavinsky S.L., Barinova A.N.

	pancreatic insufficiency in children cystic fibrosis		
62	Use of inhibitor of cycline-dependent kinase 4/6 (palbociclib) in treatment of metastatic breast cancer. A cost-consequence analysis	Siberian journal of oncology. 2017; 16(4):19-25. (In Russ.) DOI:10.21294/1814-4861-2017-16-4-19-25	Plavinsky S.L., Shabalkin P.I.
63	Assessment of the effectiveness of prevention programs for countermeasure of spread of socially important infections	Hygiene and sanitation. 2017; 96(4):392-396. DOI: 10.18821/0016-9900-2017-96-4-392-396	Barinova A.N., Khurtsilava O.G., Plavinskiy S.L.

II. Oral and Poster Presentations on Pharmacoeconomics and Health Technology Assessment at the ISPOR International and European Meetings:

№	Conference Title	Organizers	Report Title	Venue
1	ISPOR 22nd Annual International meeting	ISPOR	Pharmacoeconomic Analysis of Dexamethasone Intravitreal Implant for the Treatment	May 20-24, 2017, Boston, MA, USA.
2	20th European Congress	ISPOR	Pharmacoeconomic Analisis of Trastuzumab Emtanzine in Patients with Metastatic Breast Cancer and Central Nervous System Metastases	November 6-9, 2017, Glasgow, Scotland
3	20th European Congress	ISPOR	Pharmacoeconomic Analisis of Obinutuzumab Plus Chlorambucil in Patients with Previously Untreated Chronic Lymphocytic Leukemia and Coexisting Conditions	November 6-9, 2017, Glasgow, Scotland

4	20th European Congress	ISPOR	Pharmacoeconomic Analysis of Ixabepilone Monotherapy in Patients with Advanced or Metastatic Breast Cancer Resistant To Anthracyclines, Taxanes and Capecitabine	November 6-9, 2017, Glasgow, Scotland
5	20th European Congress	ISPOR	The Analysis Of Final And Surrogate Effectiveness Criteria Used In Health Economic Studies Of Drugs Submitted Into The Reimbursement In Russia In 2016	November 6-9, 2017, Glasgow, Scotland
6	20th European Congress	ISPOR	Analysis of Effectiveness Criteria In Pharmacoeconomic Studies of Antimicrobial Therapeutic Agents Proposed for Inclusion In The Essential Drug List (RUSSIA) In 2014-2016	November 6-9, 2017, Glasgow, Scotland

III. Reports in the field of pharmacoeconomics and health technology assessment at Russian and International conferences:

№	Conference Title	Organizers	Report Title	Venue
1	XXI Annual Scientific Session of the Pharmacology Institute named after A.V. Valdman	Pavlov First Saint Petersburg State Medical University	Evaluation of medical technologies in Russia - from theory to practice.	Saint Petersburg

2.	VIII Scientific and Practical Conference "Rational Pharmacotherapy in Therapeutic Practice" with symposium "Respiratory system Disorders"	Russian Academy of Medical Sciences, Healthcare Committee of St. Petersburg	Does the choice of medicines belong to a doctor, a patient or a state?	Saint Petersburg
3	Safety of Medicines - Acute Fundamental and Applied Questions	Healthcare Committee of St. Petersburg	Importance of drug safety in health technology assessment	Saint Petersburg
4	5th Interregional Scientific and Practical Symposium "Pharmacoeconomics of Chronic Viral Infections. Issues of economics in epidemiology, prevention, diagnosis and clinic of HIV infection and chronic hepatitis"	Russian Academy of Medical Sciences, Healthcare Committee of St. Petersburg	Pharmacoeconomics in the Russian Federation: from theory to practice. The Role of Pharmacoeconomics in Decision Making in Epidemiology and Infectious Pathology	Saint Petersburg
5	VI St. Petersburg International Forum of Otorhinolaryngologists of Russia	Ministry of Health, Healthcare Committee	Pharmacoeconomic aspects of the antibiotic therapy choice	Saint Petersburg
6	Interregional conference "Topical issues of clinical pharmacology and drug provision" (within the framework of the All-	Ministry of Health	Performance indicators used in clinical and economic studies of medicines proposed for inclusion in	Voronezh

	Russian meeting "Topical issues of clinical pharmacology and drug provision")		restrictive lists in Russia.	
7	Interregional conference "Topical issues of clinical pharmacology and drug provision" (within the framework of the All-Russian meeting "Topical issues of clinical pharmacology and drug provision")	Ministry of Health	Differential approach to the accreditation of specialists of various qualification categories in the field of clinical pharmacology	Voronezh
8	V Russian Conference with international participation "Current issues of preclinical and clinical trials of medicines, biomedical cellular products and clinical research of medical devices"	Ministry of Health; Pavlov First Saint Petersburg State Medical University	Prognosis of clinical efficacy based on clinical studies	Saint Petersburg
9	IX Congress of Russian Oncology Association	Russian Oncology Association; Ministry of Health of the Russian Federation; Russian Academy of Sciences	The problem of selecting generics in oncology. The prospects of using multi-criteria analysis methodology.	Ufa

10	III St. Petersburg International Oncology Forum «White Nights - 2017». Pharmacoeconomics in oncology Session	Ministry of Health; Russian Academy of Sciences; Healthcare Committee of St. Petersburg	Cost of additional effectiveness in oncology. The data from restrictive lists in the Russian Federation, years 2014 - 2015.	Saint Petersburg
11	St. Petersburg Septic Forum	Healthcare Committee; Local Compulsory Medical Insurance Fund	Performance indicators used in clinical and economic studies of antimicrobial agents proposed for inclusion in restrictive lists in Russia	Saint Petersburg
12	XII International Scientific Congress “Rational Pharmacotherapy”- 2017	Healthcare Committee	Analysis of effectiveness criteria for pharmaco-economic studies of drugs used in diabetes mellitus. Data of Russian restrictive lists	Saint Petersburg
13	"HIV infection and immunosuppression. Epidemiology, clinic and modern strategies. Heavy and comorbid forms of HIV infection"	Russian Academy of Medical Sciences	The modern choice of the generic drugs. International recommendations	Saint Petersburg

14	VIII Siberian Medical and Pharmaceutical Forum	The Government of Krasnoyarsk Territory	How much does the additional efficacy in oncology in Russia cost?	Krasnoyarsk
15	Regional interdisciplinary practical seminar "Issues of rendering assistance to HIV-infected women and their children in St. Petersburg"	Healthcare Committee	Pharmacoeconomic aspects of the prevention and treatment of infectious diseases	Saint Petersburg
16	Regional interdisciplinary practical seminar "Issues of rendering assistance to HIV-infected women and their children in St. Petersburg"	Healthcare Committee	Pharmacoeconomic aspects of perinatal HIV transmission	Saint Petersburg
17	IX Annual All-Russian Congress with International Participation on Infectious Diseases	Russian Academy of Medical Sciences	Budget impact analysis of various schemes of antiviral treatment of chronic hepatitis C	Moscow
18	Eurasian Expert Council "Modern Approaches to Health Technology Assessment in Case of Preventive Vaccination"	Eurasian Expert Council	Basics of prognosis of pharmacoeconomic effectiveness of children immunization against vaccine-preventable infections in the Russian Federation	Astana

19	5th Interregional Scientific and Practical Symposium "Pharmacoeconomics of Chronic Viral Infections. Issues of economics in epidemiology, prevention, diagnosis, and clinic of HIV infection and chronic hepatitis"	Russian Academy of Medical Sciences	Pharmacoeconomics of HIV therapy	Saint Petersburg
20	Workshop at the Petrov Research Institute of Oncology on the topic "The Place of Tablet Cytostatics in the Treatment of Malignant Neoplasms"	FSBI «Petrov Research Institute of Oncology» of the Ministry of Healthcare of the Russian Federation	Pharmacoeconomic aspects of malignant neoplasms therapy with oral vinorelbine	Saint Petersburg
21	Scientific conference "Pharmacoeconomics in oncology and oncohematology"	Russian Academy of Medical Sciences	Pharmacoeconomic aspects of metastatic melanoma therapy	Saint Petersburg
22	III Moscow city Conference on Clinical Pharmacology and Rational Pharmacotherapy "Votchalovsky's Readings"	Healthcare Committee	Pharmacoeconomic aspects of metastatic melanoma therapy	Moscow
23	IV Russian symposium with international participation	Russian Academy of	Pharmacoeconomic aspects of vaccination against	Saint Petersburg

	“Papillomavirus infection and cancer: a unified system of epidemiological surveillance and prevention”	Medical Sciences	papillomavirus infection	
24	International Oncology Forum “White Nights 2017”	Russian Academy of Medical Sciences	Innovative medical technologies in oncology: willingness to pay threshold	Saint Petersburg
25	ERS International conference	ERS	Pharmacoeconomic aspects of drug susceptibility testing of M. tuberculosis using automated liquid culture systems and solid media	Milano
26	Scientific workshop "Topical issues of immunotherapy of solid tumors"	Russian Academy of Medical Sciences	Pharmacoeconomic aspects of malignant neoplasms immunotherapy	Saint Petersburg
27	II St. Petersburg Forum on HIV Infection "Modern Aspects of Prevention, Diagnosis and Treatment"	Russian Academy of Medical Sciences	Costs optimization for antiviral therapy - pharmacoeconomic analysis of available treatment regimens for HCV genotype 1	Saint Petersburg
28	XII International Scientific Congress “Rational Pharmacotherapy”	Healthcare Committee	Pharmacoeconomic aspects of immunotherapy of metastatic melanoma	Saint Petersburg

			and non-small cell lung cancer	
29	International Scientific conference "HIV infection and immunosuppression. Epidemiology, clinic and modern strategies. Heavy and comorbid forms of HIV infection"	Russian Academy of Medical Sciences	Pharmacoeconomics and HIV medicine	Saint Petersburg
30	All-Russian annual congress "Infectious Diseases in Children: Diagnosis, Treatment and Prevention"	Russian Academy of Medical Sciences	Pharmacoeconomic and clinical advantages of quadrivalent influenza vaccines	Saint Petersburg
31	All-Russian scientific and practical conference of phthisiologists with international participation "Interdisciplinary approach to solving the problem of tuberculosis"	Russian Academy of Medical Sciences	Pharmacoeconomic aspects of diagnostics and control of pulmonary tuberculosis therapy using inoculation on liquid (BACTEC MGIT) and solid media	Moscow
32	XI Congress of the All-Russian Public Organization "All-Russian Scientific-Practical Society of Epidemiologists, Microbiologists and Parasitologists"	Ministry of Health	Pharmacoeconomic ground of vaccination against rotavirus infection in the Russian Federation	Moscow

	"Ensuring Epidemiological Well-Being: Challenges and Solutions"			
33	All-Russian annual scientific conference "Unresolved issues of etiotropic therapy of topical infections"	Healthcare Committee	Pharmacoeconomics of the 4-valent influenza vaccine	Saint Petersburg
34	III St. Petersburg International Oncology Forum «White Nights - 2017»	Russian Academy of Medical Sciences	ABC / VEN-analysis: the role and place in oncology	Saint Petersburg
35	XVI Assembly "Health of Moscow"	Russian Academy of Medical Sciences	Tactics of patients management of older age groups with comorbid pathology	Moscow
36	XIV annual interregional conference "Topical issues of quality assurance of medicinal and medical care"	Russian Academy of Medical Sciences	Clinical and economic evaluation of the pharmacotherapy of COPD in the real world practice of Russian public healthcare	Sochi
37	Scientific Conference "Health Technology Assessment for Orphan Diseases"	Ministry of Health	Potentialities and difficulties associated with the use of biosimilars in patients with LSD and CNS disorders	Saint Petersburg
38	Scientific Conference "Treatment of schizophrenia in a new	Ministry of Health	Pharmacoeconomic aspects of	Moscow

	model for the provision of mental health care”		paliperidone palmitate	
39	XI National Congress with international participation "Development of pharmacoconomics and pharmacoepidemiology in the Russian Federation" - "Pharmacoconomics - 2017"	Ministry of Health	Pharmacotherapy of ACS with conservative treatment tactics	Ekaterinburg
40	All-Russian meeting “Topical issues of clinical pharmacology and drug provision”	Ministry of Health	Modern pharmacotherapy of nonsmall cell lung cancer: how effective are the costs?	Voronezh
41	Conference “Issues of Diagnosis and Treatment of Melanoma and Skin Tumors”	Association of specialists on problems of melanoma	Pharmacoeconomic evaluation of the use of Zelboraf (vemurafenib) in the treatment of patients with with metastatic or unresectable skin melanoma with BRAF V600 mutation	Moscow
42	The best based on the materials of international conferences and symposiums 2017: WEST"	Russian Society of Clinical Oncology	Questions of the economic feasibility of late lines of drug therapy for breast cancer	Sochi

43	“Topical issues of clinical pharmacology and drug provision”	Association of Clinical Pharmacologists of the Russian Federation	Health economic analysis of vemurafenib in patients with metastatic or unresectable melanoma with BRAF V600 mutation	Voronezh
44	IX Congress of Russian Oncology Association	Russian Oncology Association; Ministry of Health of the Russian Federation	Patient accessibility to therapy in the third and subsequent lines of treatment for metastatic cancer	Ufa
45	IX Congress of Russian Oncology Association	Russian Oncology Association; Ministry of Health of the Russian Federation	Can innovative approaches to the therapy of metastatic breast cancer be economically feasible?	Ufa
46	III Oncology Forum of the Southern Federal District of Russia	Russian Oncology Association	Breast cancer. Pharmacoeconomic aspects of the innovative therapy	Pyatigorsk
47	12th international scientific congress “Rational Pharmacotherapy”	Healthcare committee of Saint Petersburg, Regional NGO “Professional medical	Clinical-economic aspects of pharmacotherapy for diabetic macular edema	Saint Petersburg

		Association of clinical pharmacologists of Saint Petersburg”		
48	I All-Russian Conference “The Real Way from Scientific Developments to Drugs”, November 2, 2017		Post-marketing surveillance studies	Moscow

V. The PhD thesis on "Evaluation of medical technologies for the use of insulin bioanalogues on the basis of comparative efficacy and safety clinical research data" was defended on Dec 26, 2017

VI. ISPOR Chapter Journal:

Good Clinical Practice. www.clinvest.ru

VII. Branch Interaction with authorities

1. Participation in the operation of the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health

VIII. Chapter interaction with professional organizations

1. Participation in the work of the Clinical Pharmacologist Russian Association
2. Participation in the work of the Training and Methodological Committee for Clinical Pharmacology under the Russian Federation Ministry of Health

IX. Organizational work

1. In 2017, on the Chapter initiative, the ASSOCIATION OF SPECIALISTS IN THE FIELD OF HEALTH TECHNOLOGY ASSESSMENT was registered in the Russian Federation Ministry of Justice

X. Chapter websites:

<http://www.labclinpharm.ru>

<http://www.healtheconomics.ru>